Getinge B stock reacts to Nordea downgrade as Q2 2026 earnings improve
Published on 09/11/2026 at 15:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Getinge AB (publ) B stock (ISIN SE0000202624) saw renewed attention from healthcare investors after a recent rating downgrade from Nordea coincided with a price drop of about 1.6 percent on Nasdaq Stockholm around September 9, 2026, even as second quarter 2026 earnings showed clear year-on-year improvement in profitability.
Nordea downgrade weighs on Getinge B
According to Ad-hoc-news on September 10, 2026, Getinge B stock came under pressure on Nasdaq Stockholm after Nordea lowered its recommendation on the shares from buy to hold, a change that pushed the price down by around 1.6 percent on September 9, 2026.
The same overview notes that Getinge B remained within its documented 52-week range on September 9, 2026, with the closing level described as stable relative to recent sessions but clearly below the upper end of that corridor as the downgrade added a new caution signal for the Swedish medtech group.
Q2 2026 results show stronger earnings
Recent earnings data summarized by Simply Wall St indicate that in the second quarter 2026, Getinge reported revenue of SEK 8.38 billion, an increase of 1.7 percent compared with the second quarter 2025, while net income rose to SEK 841.0 million, up 61 percent year on year.
The same Q2 2026 overview shows earnings per share of SEK 3.09 versus SEK 1.92 in the second quarter 2025, meaning EPS expanded by SEK 1.17 and improved roughly 61 percent over the prior-year quarter, with the profit margin rising to 10.0 percent from 6.0 percent in the comparable period, underlining a significant margin recovery in the latest reported quarter.
For investors, this combination of modest top-line growth and much stronger profitability in Q2 2026 suggests that Getinge has been able to improve operating efficiency or mix, even though the rating action by Nordea signals increased caution about the risk profile or valuation at the current share price.
Life Science margin context and segment focus
Segment figures reported by Placera on September 11, 2026 highlight that for the rolling 12-month period up to and including June 2026, the adjusted EBITA margin in the Life Science segment stood at 12.3 percent, providing an additional data point for investors tracking profitability across Getinge’s business areas.
In the same update, Placera lists a recent price for Getinge B of SEK 235.80, corresponding to a one-day move of minus 0.97 percent as of early trading on September 11, 2026, indicating that the shares were still trading below the SEK 236.50 level referenced in the segment discussion and that short-term volatility remained moderate despite the earlier rating downgrade.
Analyst coverage and valuation signals
Analyst coverage compiled by MarketScreener shows that UBS initiated coverage of Getinge with a neutral rating and a price target of SEK 255 on September 2, 2026, positioning the target modestly above recent trading levels and reinforcing the picture of a stock seen as fairly valued rather than strongly undervalued or overvalued by this particular house.
The Nordea downgrade to hold and the UBS neutral stance together point to a more balanced analyst view, where the improved Q2 2026 earnings and Life Science margins are weighed against valuation considerations and sector risks in the medtech and healthcare equipment space.
Trading data and relative performance
Per price data reported by MarketScreener for the Tradegate listing, Getinge B closed at EUR 20.93 on Tradegate on September 10, 2026, down 1.88 percent from the prior close, with the five-day performance at minus 2.91 percent and the year-to-date performance at plus 5.44 percent as of that date, underscoring that the stock has given back some recent gains but still shows a positive performance over the course of 2026.
Ad-hoc-news notes that on September 10, 2026 the OMX Stockholm Benchmark ESG Responsible Gross Index, which includes Getinge B among its constituents, finished at 1,384.91 points, up 0.28 percent compared with its prior close of 1,381.09, meaning Getinge B’s 1.88 percent decline on that day underperformed the home ESG benchmark by about 2.16 percentage points.
Stock level on Nasdaq Stockholm
According to Placera, Getinge B last traded around SEK 235.80 on Nasdaq Stockholm with a one-day change of minus 0.97 percent as of early trading on September 11, 2026, keeping the shares within their 52-week range and below the SEK 255 price target recently set by UBS.
Getinge B stock key data
- Company: Getinge AB (publ)
- ISIN: SE0000202624
- Ticker: GETI B
- Trading venue: Nasdaq Stockholm
- Price (as of September 11, 2026): 235.80 SEK
- Sector / Industry: Health Care Equipment
- Index membership: OMX Stockholm Benchmark ESG Responsible Gross Index
